Bone Biologics Statistics
Total Valuation
Bone Biologics has a market cap or net worth of $2.65 million. The enterprise value is -$708,297.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, before market open.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bone Biologics has 3.27 million shares outstanding. The number of shares has increased by 476.60% in one year.
| Current Share Class | 3.27M |
| Shares Outstanding | 3.27M |
| Shares Change (YoY) | +476.60% |
| Shares Change (QoQ) | +41.44% |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 2.14% |
| Float | 3.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.68 |
| P/TBV Ratio | 0.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.22
| Current Ratio | 10.22 |
| Quick Ratio | 8.80 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -128.71% and return on invested capital (ROIC) is -82.53%.
| Return on Equity (ROE) | -128.71% |
| Return on Assets (ROA) | -69.40% |
| Return on Invested Capital (ROIC) | -82.53% |
| Return on Capital Employed (ROCE) | -121.11% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.66M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.74% in the last 52 weeks. The beta is 0.93, so Bone Biologics's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | -61.74% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 1.31 |
| Relative Strength Index (RSI) | 40.75 |
| Average Volume (20 Days) | 34,873 |
Short Selling Information
The latest short interest is 76,509, so 2.34% of the outstanding shares have been sold short.
| Short Interest | 76,509 |
| Short Previous Month | 193,340 |
| Short % of Shares Out | 2.34% |
| Short % of Float | 2.37% |
| Short Ratio (days to cover) | 0.36 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -4.22M |
| Pretax Income | -5.12M |
| Net Income | -7.32M |
| EBITDA | n/a |
| EBIT | -4.22M |
| Earnings Per Share (EPS) | -$4.83 |
Full Income StatementBalance Sheet
The company has $3.33 million in cash and n/a in debt, giving a net cash position of $3.33 million or $1.02 per share.
| Cash & Cash Equivalents | 3.33M |
| Total Debt | n/a |
| Net Cash | 3.33M |
| Net Cash Per Share | $1.02 |
| Equity (Book Value) | 3.48M |
| Book Value Per Share | 1.18 |
| Working Capital | 3.48M |
Full Balance SheetCash Flow
| Operating Cash Flow | -4.12M |
| Capital Expenditures | n/a |
| Free Cash Flow | -4.12M |
| FCF Per Share | -$1.26 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |